In the ongoing struggle to find treatments — and maybe one day even a cure — for dementia, researchers are focusing their attention on high blood pressure, long believed to be a culprit for a variety of other ills and an ailment for which many drugs are already available.
This coming fall, the U.S. National Institutes of Health will start enrolling participants in the largest trial thus far to see if lowering blood pressure even below current recommendations can reduce not only the risk of age-related cognitive decline, but also the risk of cardiovascular and kidney diseases.
The Systolic Blood Pressure Intervention Trial (SPRINT) will involve 7,500 people aged 55 and over who will be followed for a minimum of four years. The NIH is investing $114 million in the endeavor.
To read the full HealthDay News story--Go Here Now.
